Low incidence of Permanent Complications During Catheter Ablation for Atrial Fibrillation using open irrigated catheters: a multicenter registry by Stabile, G. et al.
  
 
 
This is an author version of the contribution published on:  
 
Questa è la versione dell’autore dell’opera:  
 
[Europace. 2014 Aug;16(8):1154-9. doi: 10.1093/europace/euu002.] 
 
The definitive version is available at:  
La versione definitiva è disponibile alla URL:  
[http://europace.oxfordjournals.org/content/16/8/1154] 
  
2 
Low incidence of permanent complications during 
catheter ablation for atrial fibrillation using 
open-irrigated catheters: a multicentre registry 
 
Giuseppe Stabile, MD,* Emanuele Bertaglia, MD,† Alessia Pappone, MD,‡ Sakis 
Themistoclakis, MD,§ Claudio Tondo, MD, PhD,║ Vittorio Calzolari, MD,** Nicola 
Bottoni, MD,†† Giuseppe Arena, MD,‡‡ Luca Rebellato, MD,§§ Maurizio Del Greco, 
MD,║║ Antonio De Simone, MD,*** Leonardo Corò, MD,††† Andrea Avella, 
MD,‡‡‡ Matteo Anselmino, MD, PhD,§§§ and Carlo Pappone, MD, PhD. 
From: * Casa di Cura Mediterranea, Napoli; †Clinica Cardiologica, Dipartimento di 
Scienze Cardiologiche, Toraciche e Vascolari, Università degli Studi di Padova;  ‡Casa 
di Cura Villa Maria Cecilia, Cotignola (RA), §Ospedale dell’Angelo, Mestre-Venezia; 
║Centro Cardiologico Monzino, Milano; **Ospedale Ca’ Foncello, Treviso; 
††Ospedale Santa Maria Nuova, Reggio Emilia; ‡‡UOC Cardiologia ULSS 1, Massa e 
Carrara; §§Ospedale Santa Maria della Misericordia, Udine; ║║Ospedale Santa Chiara, 
Trento; ***Casa di Cura San Michele, Maddaloni (CE); †††Ospedale Civile, 
Conegliano (TV); ‡‡‡Azienda Ospedaliera San Camillo-Forlanini, Roma; 
§§§Dipartimento di Scienze Mediche, Università degli Studi di Torino; Italy. 
 
  
3 
Address for correspondence: 
Giuseppe Stabile, 
Laboratorio di Elettrofisiologia, 
Clinica Mediterranea, Via Orazio 2, 80122 Napoli 
Tel 0039817259641, Fax 0039817259777 
E-mail gmrstabile@tin.it 
  
4 
 ABSTRACT 
Aims. Despite catheter ablation (CA) has become an accepted treatment option for 
symptomatic, drug-resistant atrial fibrillation (AF), safety of this procedure continues to 
be cause for concern. Aim of the present study was to assess the incidence of 
complications with permanent sequelae of CA for AF using open irrigated catheters in a 
contemporary, unselected population of consecutive patients. 
Methods. From January 1, 2011 to December 31, 2011, data from 2,167 consecutive 
patients who underwent CA for AF using an open irrigated catheter in 29 Italian centers 
were collected. All complications occurring to the patient from admission to 30th post-
procedural days were recorded.  
Results. No procedure-related death was observed. Complications occurred in 81 
patients (3.7%): 46 patients (2.1%) suffered vascular access complications; 13 patients 
(0.6%) cardiac tamponade, successfully drained in all cases; 6 patients (0.3%) arterial 
thromboembolism (4 transient ischemic attack and 2 ischemic strokes); 5 (0.2%) 
patients conservatively treated pericardial effusion; 3 patients (0.1%) phrenic nerve 
paralysis; 3 patients (0.1%) pericarditis; 3 patients (0.1%) hemothorax, and 2 patients 
(0.1%) other isolated adverse events. At multivariate analysis, only female sex (OR 2.5, 
CI 1.5-3.7, p<001) and  operator experience (OR 0.5, CI 0.4-0.7, p<001) related to  
complications. Only 5 (0.2%) patients developed permanent sequelae from their 
complications. 
Conclusion. CA for AF with the use of open irrigated-catheters is currently affected by 
a very low rate of complications leading to permanent sequelae.  
 
KEY WORDS: atrial fibrillation; catheter ablation; permanent complications. 
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CONDENSED ABSTRACT 
We assessed the incidence of complications with permanent sequelae in 2,167 
consecutive patients who underwent catheter ablation for atrial fibrillation using open 
irrigated catheters. Complications occurred in 81 patients (3.7%). Female sex and 
operator experience were correlated with complications. Only 5 (0.2%) patients 
developed permanent sequelae from their complications. 
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What’s New 
1. This is the first multicenter study specifically aimed at collecting data regarding 
the incidence of complications with permanent sequalae in an unselected 
population of patients undergoing catheter ablation for atrial fibrillation by 
means of open irrigated catheters 
2. No procedure-related death was reported. Out of a cumulative complication rate 
of 3.7%, only 0.2% of the patients developed permanent sequelae.  
3. Complications were more frequent when catheter ablation was performed in 
females and by less experienced operators.  
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INTRODUCTION 
Catheter ablation (CA) of atrial fibrillation (AF) is a well established treatment option 
for recurrent, symptomatic, drug-resistant atrial fibrillation (AF) (1,2). Despite the 
satisfactory results justifying (3-5) the recommendation for CA by  international 
guidelines in selected patients, safety of this procedure remains cause for concern 
(1,2,6). Previous studies reported a rate of complications ranging from 3.5% to 6.3% (7-
12). These reports, however, gathered events with extremely different outcomes: from 
groin hematomas requiring few days of rest to PV stenosis with pulmonary distress and 
thromboembolic events leading to permanent disability. Only one study specifically 
focused on complications and reported prevalence and causes of fatal outcome 
following CA of AF (13). Thus, the effect on prognosis of complications recorded 
during CA for AF is unknown. Open irrigated-catheters (OIC) are widely used for 
radiofrequency CA (14) in particular of AF (15-17). In fact, OIC overcome some 
limitations of 4-mm and 8-mm Radiofrequency catheter, such as coagulum formation 
and insufficient power delivery in areas of low blood flow. However, concern has been 
raised regarding the safety of OIC, especially when used with high power, due to an 
increased occurrence of cardiovascular and gastrointestinal complications (15).  
Aim of the present study was to assess the incidence of complications with permanent 
sequelae of CA for AF using OIC in a contemporary population of consecutive patients. 
 
METHODS 
Study population. We prospectively collected clinical and procedural data concerning 
consecutive patients who underwent CA for AF in 29 Italian electrophysiology 
laboratories between January 1 and December 31, 2011 (18).  In 2,167 of these patients 
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CA was performed using an OIC, and they represented our study population. This 
observational study was approved by the local institutional review committees, and 
written informed consent was obtained from each patient. 
Anticoagulation. All patients were on oral anticoagulants (dicumarol or acenocumarol) 
with a therapeutic international normalized ratio (INR) higher than 2.0 for at least 4 
weeks preceding the procedure, or performed transesophageal echocardiographic 
assessment to exclude the presence of left atrial thrombus. Oral anticoagulants were 
withdrawn 2 or 3 days before ablation, and substituted with low molecular weight 
heparin until 12 hours before the procedure. Unfractionated heparin infusion was started 
immediately after trans-septal catheterization, to maintain the mean Activated Clotting 
Time between 300 and 400 seconds. Low molecular weight heparin was restarted 4 to 6 
hours after sheaths removal, and continued until oral anticoagulant therapy, started on 
the same day of the procedure, reached therapeutic target. 
Ablation. All ablation strategies aiming at isolating or encircling the PVs were included 
in the Registry. Additional linear lesions in the right or left atrium were also allowed. 
For the purpose of this study we report data only on CA procedures performed by 
means of OIC [Navistar® ThermoCool® or ThermoCool SF®  (Biosense Webster Inc., 
Diamond Bar, California) or Coolpath® or Cooflex® (St.Jude Medical inc. Endocardial 
Solutions St. Paul, MN, USA)]. Radiofrequency pulses were delivered with a 
temperature setting of 45° C and radiofrequency energy up to 50 W. In several centers, 
when ablation was performed in the posterior wall of the left atrium, radiofrequency 
power was usually reduced to 25 W  to avoid the risk of injuring the adjacent structures. 
In the majority of centers ablation was guided by a 3D non-fluoroscopic mapping 
system [Carto system (Biosense Webster Inc.) or EnSite NavX (St.Jude Medical 
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inc. Endocardial Solutions S. Paul, MN, USA)] creating an electroanatomical map of 
left atrium and PVs with or without integration of left atrium computed tomography or 
magnetic resonance scans.  
A circular mapping catheter was widely used to confirm PV’s electrophysiological 
isolation, and intracardiac echo imaging was used to guide the PV antrum isolation in 2  
laboratories. 
Definitions. Complications were defined as all unexpected events which required 
intervention or prolonged hospital stay beyond the scheduled period. Early 
tachyarrhythmias (AF or atrial tachycardia/flutter) were not included even if requiring 
cardioversion. 
Complications with permanent sequelae were defined as those leading to death or 
causing permanent harm not resolving within 30 days from CA. 
Procedures were done by different operators. Personal background as first operator was 
considered to classify operator’s experience: less than 100 procedures; between 101 and 
500 procedures; and more than 500 procedures. 
Data collection. The investigators were provided with the same data sheet for the 
collection of specific information on each ablation procedure. Data were collected 
retrospectively by each investigator, and sent via a computerized database in Excel 
format (Windows 7, XP, or Mac) to the coordinating center for analysis. Each author 
took responsibility for data integrity.  
The Registry considered complications occurring from hospital admission of the patient 
to the 30th post-procedural day. Complications occurring after the hospital stay and 
clinical status of patients developingcomplications were collected through out-patient 
visit or telephone interview. 
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Statistical analysis. Normally distributed continuous variables were expressed as 
means (SD) and compared by Student's T-Test. Normality was assessed using the 
Shapiro-Wilk test. Skewed variables were expressed as medians (quartiles) and 
compared by runk-sum test. Categorical variables were presented as counts and 
percentages, and compared by chi-square or Fisher’s exact test, as appropriate. A 
logistic regression model was designed and stepwise backward selection was performed 
in order to identify significant and independent predictors of complications. 
Independent variables were chosen when a p value < 0.10 emerged at univariate 
analysis. The starting model included: gender; age; and operator’s experience. A 
significant increase in risk was obtained if the 95% confidence interval exceeded 1 and 
the p value of the Wald test was <0.05.  
Analysis was performed by means of SPSS (version 11.0, SPSS Inc., Chicago, Illinois, 
USA). 
 
RESULTS 
Clinical and procedural data. The final patient cohort included 2,167 consecutive 
patients. Baseline clinical characteristics of the study population are shown in Table 1, 
while procedural data are listed in Table 2. 
Complications. No procedure-related death was observed. Complications occurred in 
81 patients (3.7%): 46 patients (2.1%) suffered vascular access complications; 13 
patients (0.6%) developed cardiac tamponade, successfully drained in all cases; 6 
patients (0.3%) had arterial thromboembolism (4 transient ischemic attack and 2 
ischemic strokes); 5 patients (0.2%) presented pericardial effusion not requiring specific 
intervention; 3 patients (0.1%) had phrenic nerve paralysis during right PV isolation; 3 
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patients (0.1%) had pericarditis; 3 patients (0.1%) had hemothorax requiring drainage in 
2 cases. Other isolated but serious adverse events were documented in 2 patients 
(0.1%): hemorragic stroke in 1; transient ST elevation in 1. 
In Table 3 clinical and procedural characteristic of patients with and without 
complications are shown. At univariate analysis, patients with complications were older 
and more frequently females, and ablation was less frequently performed by 
experienced operators. At multivariate analysis, female gender (OR 2.5, CI 1.5-3.7, 
p<001) predicted complications, while higher operator experience (OR 0.5, CI 0.4-0.7, 
p<001) inversely related to complications. 
Complications with permanent sequelae. Out of all complications 5 (0.2%) did not 
result transient: 3 permanent neurological sequelae (2 ischemic and 1 hemorragic 
stroke), and 2 permanent symptomatic phrenic nerve palsy. Clinical and procedural 
characteristics of patients with permanent complications are presented in Table 4. 
 
DISCUSSION 
Main findings. This is the first multicenter study specifically aimed at collecting data 
regarding the incidence of complications with permanent sequalae in an unselected 
population of patients undergoing  CA for AF by means of OIC. No procedure-related 
death was reported. Out of a cumulative complication rate of 3.7%, only 0.2% of 
patients developed permanent sequelae. Complications were more common when CA 
was performed in females and by less experienced operators.  
Complications in CA for AF. The demonstration of superiority of CA over 
antiarrhythmic therapy in the management of several settings of AF patients (3-5) has 
greatly increased the procedure recommendation in the last decade (19,20). Despite 
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technological improvements, CA of AF is still affected by an high amount of 
complications mainly related to the extension of lesions in the left atrium, the need of a 
deep anticoagulation and the increasing number of centers starting to approach AF 
ablation (12,17,21). Thromboembolic complications seem to be affected by ablation 
technologies and by energy (22,23). In particular, OICs have been reported to reduce the 
risk of thrombus formation at the electrode-tissue interface, and the risk of steam pop 
(24). On the other hand, OICs deliver a large amount of saline solution during 
prolonged ablation procedures, and make deeper and larger lesions that might increase 
the risk of pericardial effusion or perforation.  
Our study is the first to be designed to evaluate the complications during radiofrequency 
CA for AF by means of OICs, with an overall complication rate of 3.7%, slightly lower 
than that reported by recent multicenter studies using different technologies (12,18,21). 
Also the rate of thromboembolic complications (0.3%) and pericardial effusion or 
cardiac tamponade (0.8%) seems to confirm the safety of OICs, as recently reported 
(14,16,17).  
We found an increase of complication rate when procedures were performed by less 
experienced operators. This finding is consistent with the observation that  operators’ 
experience and hospital volume related to better outcomes (12,21). 
Complications with permanent sequelae. The more feared complications of CA are 
obviously those leading to death or to permanent sequelae (13). In the present study 
only a 0.2% of permanent sequelae was reported. Two of these were permanent 
symptomatic phrenic nerve palsy occurred during ablation of the right PVs. Impedance 
monitoring, avoiding high vein values, and strict monitoring of phrenic nerve function 
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by means of regular pacing of the nerve are crucial to avoid this complication, and 
should become mandatory during ablation especially of the right PVs. 
Most of permanent complications were related to embolic events. This observation 
underlines once again the need of an aggressive procedural and periprocedural 
anticoagulation regimen. In particular, maintaining an ACT value ≥ 350 msec during 
ablation, and performing the procedure on warfarin have been effective in reducing such 
complications (25). 
Previous registries (12,13,21) have reported a rate of death ranging from 0.1% to 
0.46%. Although the low rate of death could require larger study populations to assess 
its true incidence, the lack of procedure-related death observed in our study further 
supports the safety of OICs.   
Limitations. Unfortunately we did not have a control group of patients undergoing CA 
with different technologies, like cryoablation or multielectrode catheters associated with 
duty-cycled radiofrequency energy. For this reason any conclusion on the superiority of 
one tool over the others can be driven from the present study. However the safety 
profile of the OICs seems to be evident when comparing the present to previously 
published data.  
By study design data collection focused on complications occurring within one month 
after ablation: some rare but feared complications like PV stenosis and late pericardial 
tamponade could be underrepresented.      
Clinical implications. Complications with permanent sequelae in CA for AF with the 
use of OICs are very rare and mostly related to embolic events. Based on this evidence 
it becomes acceptable to pay a higher potential risk of hemorrhagic events to reduce 
dreadful cerebral embolic complications, particularly in female. Overall rate of 
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complications of CA for AF by mean of OICs is below 4% but the hazard is increased 
when CA is performed by less experienced operators arising once again the issue to 
recommend a volume threshold to enhance safety of the procedure. 
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APPENDIX 
 
The following centers and investigators participated in the study: Azienda Ospedaliera 
Careggi, Firenze: L Padeletti, P Pieragnoli; Azienda Ospedaliera San Camillo-Forlanini, 
Roma: A Avella, P De Girolamo, F Laurenzi, A Pappalardo; Casa di Cura 
Mediterranea, Napoli: A Iuliano, G Stabile, P Turco; Casa di Cura Montevergine, 
Mercogliano (AV): F Donnici, F Solimene; Casa di Cura San Michele Maddaloni (CE): 
A. De Simone, V. La Rocca, P Turco; Casa di Cura Villa Maria Cecilia, Cotignola 
(RA): A Pappone, C Pappone; Centro Cardiologico Monzino, Milano: G Fassini, S 
Riva, C Tondo; Fondazione Poliambulanza, Brescia: P Berra, F Morandi, D Pecora; 
Istituto Clinico Città Studi, Milano; G Augello, A Santagostino, SL D’Ascia; Istituto 
Clinico Humanitas Mater Domini, Castellanza (VA): A Sanzo, M Tritto; Istituto Clinico 
Sant’Ambrogio, Milano: V De Sanctis, M Mantica, S Panigada; Ospedale Ca’ Foncello, 
Treviso: M Crosato, V Calzolari, R Mantovan; Ospedale Cisanello, Pisa: MG 
Bongiorni, E Soldati; Ospedale Civile, Arezzo: R Guida, A Fraticelli, P Notarstefano; 
Ospedale Civile, Conegliano (TV): L Corò, P Delise; Ospedale Civile, Mirano (VE): G 
Brandolino, F Zoppo; Ospedale Civile, Perugia: Zingarini; Ospedale Francesco Miulli, 
Acquaviva delle Fonti (BA): M Grimaldi, G Katsouras, F Quadrin; Ospedale Pietro 
Cosma, Camposampiero (PD): S Baccilieri, P Turrini, R Verlato; Ospedale Sandro 
Pertini, Roma: A Castro, ML Loricchio, F Turreni; Ospedale San Filippo Neri, Roma: C 
Pandozi; Ospedale Santa Chiara, Trento: M Del Greco, M Marini; Ospedale 
dell’Angelo, Mestre-Venezia: P China, A Rossillo, S Themistoclakis;  Ospedale Santa 
Maria della Misericordia, Udine: D Murer, A Proclemer, L Rebellato; Ospedale Santa 
Maria Nuova, Reggio Emilia: N Bottoni, M Iori, F Quartieri; Policlinico Casilino, 
Roma: L Calò, L De Luca, E De Ruvo, L Sciarra; Policlinico Gemelli, Roma: ML 
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Narducci, G Pelargonio; Policlinico San Matteo, Pavia: E Landolina, R Rordorf; UOC 
Cardiologia ULSS 1, Massa e Carrara: G Arena, C Bartoli, V Borrello, M Ratti. 
Coordinators: E Bertaglia, G Stabile. 
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Table 1:  Baseline clinical characteristics of the 2,167 enrolled patients  
 
 
Male gender (%) 74.8 
Age (years) 60 (52-67) 
Duration of AF history (years)  3.0 (2-6) 
Arrhythmic profile (%)  
   Paroxysmal AF 52.0 
Persistent AF 27.3 
 Permanent AF 20.7 
CHADS2 score┼ 1 (0-1) 
Mean left atrial diameter (mm)  42.0 (40-46)  
Mean left ventricular ejection fraction (%) 57.4 (6.7)  
 
Continuous variables are presented as mean (SD) or median (25%-75%iles). 
AF=atrial fibrillation; REDO=patients who had already undergone PV catheter ablation. 
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Table 2:  Procedural data of the 2,167 enrolled patients  
 
 
 
Continuous variables are presented as mean (SD) or median (25%-75%iles). 
*: analysis based on 1920 subjects; ┼:analysis based on 1775 subjects. 
MRI= magnetic resonance imaging; CT= computed tomography; CTI=cavo-tricuspidalic isthmus; 
LA=left atrium; PV=pulmonary vein; RF=radiofrequency; TEE=transoesophageal 
echocardiography.  
Pre-ablation imaging (%)   
 MRI 13.0 
 CT 22.0 
 TEE 49.0 
Mapping system (%)   
 None 7.0 
 CARTO 56.9 
 NAVx 36.0 
 Other 0.1 
Number of vascular accesses  3.0 (3-5) 
Number of trans-septal punctures  1 (1-1) 
Number of ablated PVs  4 (4-4) 
CTI ablation (%)   19.2 
Mitral to inferior left PV isthmus ablation  (%)  40.3 
Left atrial roof ablation (%)  43.1 
Duration of fluoroscopy exposure (minutes)*  22 (13-43) 
Duration of RF delivery (minutes)┼  31 (24-39) 
Ongoing warfarin (%)  6.0 
Learning curve level (%)   
 <100 patients 6.0 
 101-500 patients 22.0 
 >501 patients 70.0 
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Table 3. Univariate analysis for comparisons between patients with and without 
complications. 
 No complications 
N=2084 
Complications 
N=81 
p 
Age (years) 60 (53-66)  64 (60-68) 0.03 
Male gender (%) 72.7 53.1 <0.001 
CHADS2 score 1 (0-1) 1 (0-1) 0.49 
Arrhythmic profile (%) 
  Paroxysmal  
Persistent  
 Permanent  
  Duration of AF history (years) 
 
51.7 
27.6 
20.7 
4 (2-6) 
 
61.7 
21.0 
17.3 
3 (2-5) 
 
0.50 
 
 
0.12 
Mean left atrial diameter (mm) 
Left ventricular  ejection fraction <55% (%) 
41 (40-45) 
18.0 
42 (40-45) 
14.8 
0.25 
0.27 
  Pre-ablation imaging (%) 
TEE 
 MRI 
                                 CT 
 
49.0 
13.0 
23.3 
 
44.4 
8.6 
28.4 
 
0.36 
   ICE (%) 12.7 16.0 0.67 
Mapping system (%) 
None 
    CARTO 
 NAVx 
Other 
 
7.1 
56.9 
35.9 
0.1 
 
6.2 
55.5 
38.3 
0 
 
0.92 
Number of vascular accesses 
Number of transseptal punctures  
Number of isolated PV 
CTI ablation (%) 
Mitral to inferior isthmus ablation (%) 
3 (3-5) 
1 (1-1) 
4 (4-4) 
19.1 
40.6 
3 (3-4) 
1 (1-1) 
4 (4-4) 
21.0 
33.3 
0.34 
0.38 
0.73 
0.68 
0.19 
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Left atrial roof ablation (%) 
Duration of fluroscopy exposure (minutes) 
Duration of RF delivery (minutes) 
Ongoing warfarin (%) 
43.4 
21 (13-41) 
30 (24-40) 
5.7 
34.6 
33 (14-49) 
33 (24-38) 
6.1 
0.11 
0.23 
0.11 
1.0 
Learning curve level (%) 
< 100 patients 
   101-500 patients 
> 501 patients 
 
5.7 
21.5 
72.8 
 
11.1 
35.8 
53.1 
 
<0.001 
 
Abbreviation as in Table 3. 
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Table IV: Clinical and procedural characteristics of the 5 patients with permanent 
complications. 
 
 Complication Gender Age CHADS2 Type of AF Hypertension CHF Diabetes Previous 
Stroke/TIA 
#1 PNP Female 60 2 Paroxysmal  1 0 1 0 
#2 PNP Female 62 1 Paroxysmal  1 0 0 0 
#3 Hemorragic 
stroke 
Male 69 1 Persistent  0 0 0 0 
#4 Ischemic stroke Female 72 1 Persistent  1 0 0 0 
#5 Ischemic stroke Female 75 6 Persistent  1 0 1 1 
  
PNP: phrenic nerve palsy; AF= atrial fibrillation; CHF= congestive heart failure; TIA= transient 
ischemic attack. 
